CA biotech develops COVID-19 nasal spray which protects up to 10 hours


A small Emeryville, CA biotech firm is developing InvisiMask, a self-administered nasal spray, that protects against SARS-CoV-2 infection, the novel coronavirus that causes COVID-19, for up to 10 hours in early animal studies. The hope would be to offer an added layer of protection by neutralizing the virus when it enters the nose and stopping it from replicating in the body.  

Eureka Therapeutics’ InvisiMask human antibody nasal spray is designed to neutralize SARS-CoV-2 from airborne droplets and particles in the nasal cavity, the primary entry point of infection. Researchers found that the antibody binds to 20 different SARS-CoV-2 variants, including the highly infectious D614G mutation with high affinity and specificity.

The company is now working with the U.S. Food and Drug Administration to apply for an Investigational New Drug application to advance InvisiMask nasal spray into human clinical trials next year.

According to Cheng Liu, President and CEO of Eureka Therapeutics,” “We envision a daily nasal spray that functions like an invisible mask in slowing the spread of COVID-19. Anti-SARS-CoV-2 antibodies have demonstrated their effectiveness in treating patients with confirmed cases of COVID-19 and the FDA recently granted two companies emergency use authorization to use them intravenously as a therapeutic. Using antibodies in a preventive nasal spray adds to the arsenal of tools that we have to fight the spread of COVID-19, and the concept can be applied to other airborne diseases.”

“A preventive nasal spray is a complement to vaccines, therapeutics and other preventive measures,” said Jan Lin, MD, a frontline physician treating COVID-19 patients in San Jose, California. “Certain populations such as young children, seniors, frontline health workers, athletes, people with severe allergies, or immunocompromised patients could benefit immediately from a nasal spray.”

Eureka is preparing an Investigational New Drug application with the U.S. Food and Drug Administration for a clinical trial of the InvisiMask nasal spray.